Csenge Advisory Group Buys New Shares in Ascendis Pharma A/S $ASND

Csenge Advisory Group bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,946 shares of the biotechnology company’s stock, valued at approximately $628,000.

Several other large investors have also recently bought and sold shares of ASND. Advisory Services Network LLC acquired a new stake in Ascendis Pharma A/S during the third quarter worth $26,000. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the period. Quadrant Capital Group LLC bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth about $74,000. Farther Finance Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 15.1% during the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 72 shares during the period. Finally, Ninepoint Partners LP bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth about $149,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ASND shares. The Goldman Sachs Group reaffirmed a “buy” rating and set a $255.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Barclays raised their price objective on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Oppenheimer raised their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, Bank of America raised their price objective on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Trading Up 2.6%

Shares of Ascendis Pharma A/S stock opened at $247.51 on Friday. The stock has a market capitalization of $15.44 billion, a P/E ratio of 28.55 and a beta of 0.41. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The company has a 50-day simple moving average of $232.29 and a 200 day simple moving average of $221.64. Ascendis Pharma A/S has a 12-month low of $153.49 and a 12-month high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. Research analysts expect that Ascendis Pharma A/S will post 12.19 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.